COMMUNIQUÉS West-GlobeNewswire

Vantive to Invest More Than $1 Billion in Advancing Kidney Care and Vital Organ Support Through Digitally-Enabled Therapies
02/06/2025
Five-year global investment to fuel R&D and manufacturing expansion, supporting development of new technologies and services designed to improve therapy access, care experience and outcomes for patients Company to [...]
Precede Biosciences Presents ASCO 2025 Data Highlighting the Ability of its Liquid Biopsy Platform to Reveal the Biology Underlying Response and Resistance to ADCs and Radiopharmaceuticals
02/06/2025
Using just 1mL of plasma, the Precede Bio platform identified key molecular pathways linked to response and resistance in patients with metastatic breast and prostate cancer treated with sacituzumab govitecan and 177Lu- [...]
Wildfire Smoke is Already Suffocating Canada – Here’s How to Save Your Lungs
02/06/2025
As Air Quality Plummets Early in Wildfire Season, Lung Health Foundation Shares Five Essential Tips to Protect Yourself Ahead of Clean Air Day TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- With wildfire season already [...]
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
02/06/2025
Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT settings NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a [...]
The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma
02/06/2025
One-time Amtagvi Treatment Continues to Show Deep, Durable Responses and Meaningful Survival One Third of Responses Remain Ongoing without Subsequent Treatment after Five Years Simultaneous Presentation at ASCO 2025 SAN [...]
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
02/06/2025
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Global Healthcare [...]
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
02/06/2025
REYKJAVIK, Iceland, June 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its [...]
Cytrellis Strengthens Leadership Team in Support of Accelerated Commercial Growth of ellacor® Platform
02/06/2025
WOBURN, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Cytrellis Biosystems Inc., a medical technology company specializing in novel aesthetic solutions, today announced the appointment of Karyn Siemasko, Ph.D., as Vice [...]
Evosep unveils new instrumentation and partnership at ASMS 2025
02/06/2025
BALTIMORE, Md., June 02, 2025 (GLOBE NEWSWIRE) -- Evosep ® , a global leader in proteomics solutions, is proud to announce the launch of the Evosep Eno™, a robust, high-throughput separation tool preparing for next [...]
Solera Health Unveils Enhanced AI Governance Framework for Responsible and Transparent Use of Artificial Intelligence in Digital Health
02/06/2025
Framework Sets an Industry Benchmark for Client Trust and Ethical AI Use to Ensure Patient Safety and Accountability PHOENIX, June 02, 2025 (GLOBE NEWSWIRE) -- Solera Health , the premier digital health delivery company [...]
Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
02/06/2025
TRIgnite-1 study shows an overall response rate (ORR) of 74% across nine dose levels, in heavily pretreated patients with a median of six prior lines of therapy ORR is remarkably high in patients with no prior CAR-T or [...]
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
02/06/2025
MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via ultra-sensitive [...]
Liberation Labs is Now Liberation Bioindustries
02/06/2025
New name, new brand better reflects the company’s position as a global, commercial-scale biomanufacturer RICHMOND, Ind., June 02, 2025 (GLOBE NEWSWIRE) -- Liberation Labs has a new name and brand – Liberation [...]
PathAI and Northwestern Medicine Announce Strategic Collaboration to Deploy the AISight® Digital Pathology Platform and Co-Develop New AI Diagnostics
02/06/2025
Collaboration includes use of PathAI’s AISight®¹ digital pathology image management system at Northwestern Medicine and joint efforts in research, clinical innovation, and algorithm co-development to advance pathology- [...]
New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression
02/06/2025
SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
02/06/2025
- Expert Insights on Clinical Relevance and Scientific Rationale - The replay of the event is available on the Investor Relations section of the Actuate website CHICAGO and FORT WORTH, Texas, June 02, 2025 (GLOBE [...]
TerrAscend Announces Chief Financial Officer Transition Plan
02/06/2025
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND, OTCQX: TSNDF) , a leading North American cannabis company, today announced that Keith Stauffer, Chief Financial [...]
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
02/06/2025
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
02/06/2025
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets Leadership team realigned in order to enable execution of ancillary protein strategy Dyadic is well [...]

Pages